• Find people
• Intranet

Selected publications

• Heeke S, Gay CM, Estecio MR, Tran H, Morris BB, Zhang B, Tang X, Raso MG, Rocha P, Lai S, Arriola E, Hofman P, Hofman V, Kopparapu P, Lovly CM, Concannon K, De Sousa LG, Lewis WE, Kondo K, Hu X, Tanimoto A, Vokes NI, Nilsson MB, Stewart A, Jansen M, Horváth I, Gaga M, Panagoulias V, Raviv Y, Frumkin D, Wasserstrom A, Shuali A, Schnabel CA, Xi Y, Diao L, Wang Q, Zhang J, Van Loo P, Wang J, Wistuba II, Byers LA, Heymach JV. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell. 2024 Jan 24:S1535-6108(24)00006-0. doi: 10.1016/j.ccell.2024.01.001. Online ahead of print. PMID: 38278149
• Clavé S, Jackson JB, Salido M, Kames J, Gerding KMR, Verner EL, Kong EF, Weingartner E, Gibert J, Hardy-Werbin M, Rocha P, Riera X, Torres E, Hernandez J, Cerqueira G, Nichol D, Simmons J, Taus Á, Pijuan L, Bellosillo B, Arriola E. Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer. Front Oncol. 2023 Oct 20;13:1225646. doi: 10.3389/fonc.2023.1225646. eCollection 2023. PMID: 37927472
• Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K; LIBRETTO-431 Trial Investigators. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. N Engl J Med. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457. Epub 2023 Oct 21. PMID: 37870973 Clinical Trial.
• Rocha P, Rodrigo M, Moliner L, Menendez S, Masfarré L, Navarro N, Del Rey-Vergara R, Galindo-Campos M, Taus Á, Giner M, Sanchez I, Rodríguez-Fuster A, Aguiló R, Chalela R, Sánchez-Font A, Belda J, Curull V, Pijuan L, Casadevall D, Clavé S, Bellosillo B, Perera-Bel J, Comerma L, Arriola E. Pre-existing tumor host immunity characterization in resected non-small cell lung cancer. Lung Cancer. 2023 Jul;181:107257. doi: 10.1016/j.lungcan.2023.107257. Epub 2023 May 20. PMID: 37263182
• Rocha P, Ramal D, Ripoll E, Moliner L, Corbera A, Hardy-Werbin M, Orrillo M, Taus Á, Zuccarino F, Gibert J, Perera-Bel J, Casadevall D, Arriola E. Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC. JTO Clin Res Rep. 2020 Oct 28;2(1):100115. doi: 10.1016/j.jtocrr.2020.100115. eCollection 2021 Jan. PMID: 34589976
• Taus Á, Camacho L, Rocha P, Hernández A, Longarón R, Clavé S, Fernández-Ibarrondo L, Salido M, Hardy-Werbin M, Fernández-Rodríguez C, Albanell J, Bellosillo B, Arriola E. Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung Adenocarcinoma. Arch Bronconeumol (Engl Ed). 2021 May;57(5):323-329. doi: 10.1016/j.arbres.2020.01.023. Epub 2020 Apr 3. PMID: 32253118
• Gibert J, Clavé S, Hardy-Werbin M, Taus Á, Rocha P, Longarón R, Piquer G, Chaib I, Carcereny E, Morán T, Salido M, Dalmases A, Bellosillo B, Arriola E. Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.Lung Cancer. 2020 Feb;140:42-45. doi: 10.1016/j.lungcan.2019.12.003. Epub 2019 Dec 5. PMID: 31862576
• Hardy-Werbin M, Del Rey-Vergara R, Galindo-Campos MA, Moliner L, Arriola E. MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside. Cancers (Basel). 2019 Sep 20;11(10):1404. doi: 10.3390/cancers11101404. PMID: 31547040
• Hardy-Werbin M, Rocha P, Arpi O, Taus Á, Nonell L, Durán X, Villanueva X, Joseph-Pietras D, Nolan L, Danson S, Griffiths R, Lopez-Botet M, Rovira A, Albanell J, Ottensmeier C, Arriola E. Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer. Oncoimmunology. 2019 Mar 27;8(6):e1593810. doi: 10.1080/2162402X.2019.1593810. eCollection 2019. PMID: 31069160
• Clavé S, Rodon N, Pijuan L, Díaz O, Lorenzo M, Rocha P, Taus Á, Blanco R, Bosch-Barrera J, Reguart N, de la Torre N, Oliveras G, Espinet B, Bellosillo B, Puig X, Arriola E, Salido M. Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns. Clin Lung Cancer. 2019 Jul;20(4):e421-e429. doi: 10.1016/j.cllc.2019.02.008. Epub 2019 Feb 26. PMID: 30898567
• Rocha P, Arriola E. Immunotherapy is Here to Stay: A New Treatment Paradigm in Lung Cancer. Arch Bronconeumol. 2018 Oct 5
• Arriola E, Paredes-Lario A, García-Gomez R, Diz-Tain P, Constenla M, García-Girón C, Márquez G, Reck M, López-Vivanco G. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS. Clin Transl Oncol. 2018 Oct;20(10):1261-1267
• Rocha P, Hardy-Werbin M, Naranjo D, Taus Á, Rodrigo M, Zuccarino F, Roth R, Wood O, Ottensmeier CH, Arriola E. CD103+CD8+ Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC. J Thorac Oncol. 2018 Oct;13(10):e193-e196.
• Moliner L, Fernández C, Clavé S, Arriola E. Accurate Identification of Predictive Biomarkers of Response to Targeted Therapies in Lung Cancer With Next Generation Sequencing. Arch Bronconeumol. 2018 Sep 20. pii: S0300-2896(18)30304-1.
• Taus Á, Camacho L, Rocha P, Hardy-Werbin M, Pijuan L, Piquer G, López E, Dalmases A, Longarón R, Clavé S, Salido M, Albanell J, Bellosillo B, Arriola E. Dynamics of EGFR Mutation Load in Plasma for Prediction of Treatment Response and Disease Progression in Patients With EGFR-Mutant Lung Adenocarcinoma. Clin Lung Cancer. 2018 Sep;19(5):387-394.e2.
• Arriola E, García Gómez R, Diz P, Majem M, Martínez Aguillo M, Valdivia J, Paredes A, Sánchez-Torres JM, Peralta Muñoz S, Barneto I, Gutierrez V, Andrade Santiago JM, Aparisi F, Isla D, Ponce S, Vicente Baz D, Artal A, Amador M, Provencio M. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. BMC Cancer. 2018 Jan 30;18(1):106.
• Clavé S, Pijuan L, Casadevall D, Taus Á, Gimeno J, Hernández-Llodrà S, Rodríguez-Rivera M, Lorenzo M, Menéndez S, Albanell J, Espinet B, Arriola E, Salido M. CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous-cell and adenocarcinoma patients. Histopathology. 2018 Jan;72(2):259-269.
• Hardy-Werbin M, Arpí O, Taus A, Rocha P, Joseph-Pietras D, Nolan L, Danson S, Griffiths R, Lopez-Botet M, Rovira A, Albanell J, Ottensmeier CH, Arriola E. Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab. Oncoimmunology. 2017 Nov 27;7(2):e1395125.
• Casadevall D, Clavé S, Taus Á, Hardy-Werbin M, Rocha P, Lorenzo M, Menéndez S, Salido M, Albanell J, Pijuan L, Arriola E. Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples. Clin Lung Cancer. 2017 Nov;18(6):682-691.e5.
• Arriola E, Wheater M, Galea I, Cross N, Maishman T, Hamid D, Stanton L, Cave J, Geldart T, Mulatero C, Potter V, Danson S, Woll PJ, Griffiths R, Nolan L, Ottensmeier C. Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. J Thorac Oncol. 2016 Sep;11(9):1511-21.
• Arriola E, Wheater M, Lopez MA, Thomas G, Ottensmeier C. Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis. Oncoimmunology. 2016 Jul 15;5(9):e1209615. eCollection 2016.
• Arriola E, Ottensmeier C. TG4010: a vaccine with a therapeutic role in cancer. Immunotherapy. 2016 May;8(5):511-9. doi: 10.2217/imt-2016-0015. Review. PubMed PMID: 27140406.
• Clavé S, Gimeno J, Muñoz-Mármol AM, Vidal J, Reguart N, Carcereny E, Pijuan L, Menéndez S, Taus Á, Mate JL, Serrano S, Albanell J, Espinet B, Arriola E, Salido M. ROS1 copy number alterations are frequent in non-small cell lung cancer. Oncotarget. 2016 Feb 16;7(7):8019-28.
• Arriola E, Wheater M, Karydis I, Thomas G, Ottensmeier C. Infliximab for IPILIMUMAB-Related Colitis-Letter. Clin Cancer Res. 2015 Dec 15;21(24):5642-3.
• Cañadas I, Taus Á, Villanueva X, Arpí O, Pijuan L, Rodríguez Y, Menéndez S, Mojal S, Rojo F, Albanell J, Rovira A, Arriola E. Angiopoietin-2 is a negative prognostic marker in small cell lung cancer. Lung Cancer. 2015 Nov;90(2):302-6. doi: 10.1016/j.lungcan.2015.09.023. Epub 2015 Sep 26.
• Arriola E, Wheater M, Krishnan R, Smart J, Foria V, Ottensmeier C. Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control. Oncoimmunology. 2015 May 27;4(10):e1040218. eCollection 2015 Oct.
• Arriola E, Taus Á, Casadevall D. Is there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer? World J Clin Oncol. 2015 Aug 10;6(4):45-56. doi: 10.5306/wjco.v6.i4.45. Review.
• Casadevall D, Gimeno J, Clavé S, Taus Á, Pijuan L, Arumí M, Lorenzo M, Menéndez S, Cañadas I, Albanell J, Serrano S, Espinet B, Salido M, Arriola E. MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC). Oncotarget. 2015 Jun 30;6(18):16215-26.
• Vidal J, Clavé S, de Muga S, González I, Pijuan L, Gimeno J, Remón J, Reguart N, Viñolas N, Gironés R, Bernet L, Majem M, Bosch-Barrera J, Porta R, Alonso N, Palmero R, Taus A, Albanell J, Espinet B, Salido M, Arriola E. Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients. J Thorac Oncol. 2014 Dec;9(12):1816-20.
• Cañadas I, Taus A, González I, Villanueva X, Gimeno J, Pijuan L, Dómine M, Sánchez-Font A, Vollmer I, Menéndez S, Arpí O, Mojal S, Rojo F, Rovira A, Albanell J, Arriola E. High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients. Oncotarget. 2014 Jul 30;5(14):5246-56.
• Taus Á, Aguiló R, Curull V, Suárez-Piñera M, Rodríguez-Fuster A, Rodríguez de Dios N, Pijuan L, Zuccarino F, Vollmer I, Sánchez-Font A, Belda-Sanchis J, Arriola E. Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancer. Arch Bronconeumol. 2014 Mar;50(3):99-104.
• Cañadas I, Rojo F, Taus Á, Arpí O, Arumí-Uría M, Pijuan L, Menéndez S, Zazo S, Dómine M, Salido M, Mojal S, García de Herreros A, Rovira A, Albanell J, Arriola E. Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer. Clin Cancer Res. 2014 Feb 15;20(4):938-50. doi: 10.1158/1078-0432.CCR-13-1330. Epub 2013 Nov 27.